Hypertension (High Blood Pressure) and CADASIL

A recently published article discusses the findings of a study on how different antihypertensive drugs affect microvascular function in patients with small vessel disease (SVD), including those with CADASIL.

Here’s what it means for CADASIL patients:

  • Objective of the Study: The research aimed to see if different classes of blood pressure-lowering drugs have varying effects on the microvasculature (small blood vessels) of people with small vessel diseases, such as CADASIL.
  • Methodology: This was a multi-center trial that had participants from two groups: those with sporadic SVD and those with CADASIL. The participants were given three different antihypertensive medications in a random sequence, with each medication given for 4 weeks and a 2-week washout period in between.
  • Primary Measurement: The study used blood oxygen level-dependent MRI to assess changes in cerebrovascular reactivity (CVR), which is the ability of blood vessels to change diameter and thus control blood flow in response to changes in carbon dioxide levels.
  • Results: For people with sporadic SVD, the change in CVR did not significantly differ between the medications. However, for CADASIL patients, the study found significant differences. Amlodipine and losartan were both found to improve CVR compared to atenolol.
  • Interpretation for CADASIL Patients: The findings suggest that for CADASIL patients, certain antihypertensive medications might be more beneficial in improving microvascular function than others. Specifically, amlodipine and losartan showed a positive impact on CVR, which could be indicative of better overall microvascular health in CADASIL when using these drugs.
  • Clinical Implications: This study indicates that there may be a preferential choice of antihypertensive medication in CADASIL patients to improve microvascular function. However, the study points out that more research is needed to see if these changes in CVR translate to better clinical outcomes.
  • Limitations and Further Research: The abstract notes that the study was terminated and suggests the need for further research to determine if the observed effects on CVR have a meaningful impact on the progression or symptoms of CADASIL and other small vessel diseases.

In summary, for CADASIL patients, this study provides evidence that may guide the choice of antihypertensive medication, potentially favoring amlodipine or losartan over atenolol to improve blood vessel function. However, it remains to be seen how these findings affect long-term health outcomes in CADASIL. Further studies are required to explore the clinical significance of these findings.

Subscribe to our newsletter